Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Chemotherapy + Blinatumomab vs hyperCVAD in Ph- B-ALL
NCT06250959Phase 2Recruiting
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) (2 arms). Primary endpoint: Composite complete remission rate at Day 28. Started Feb 2024; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06250959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250959.